KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Guardant Health (GH) EBIT (2017 - 2026)

Guardant Health's EBIT history spans 9 years, with the latest figure at -$120.8 million for Q4 2025.

  • On a quarterly basis, EBIT rose 4.1% to -$120.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$437.2 million, a 1.43% increase, with the full-year FY2025 number at -$437.2 million, up 1.43% from a year prior.
  • EBIT hit -$120.8 million in Q4 2025 for Guardant Health, down from -$99.0 million in the prior quarter.
  • Over the last five years, EBIT for GH hit a ceiling of -$97.6 million in Q2 2021 and a floor of -$197.5 million in Q4 2023.
  • Historically, EBIT has averaged -$120.0 million across 5 years, with a median of -$115.4 million in 2023.
  • Biggest five-year swings in EBIT: tumbled 208.96% in 2021 and later skyrocketed 36.22% in 2024.
  • Tracing GH's EBIT over 5 years: stood at -$98.2 million in 2021, then crashed by 48.79% to -$146.1 million in 2022, then tumbled by 35.17% to -$197.5 million in 2023, then skyrocketed by 36.22% to -$126.0 million in 2024, then grew by 4.1% to -$120.8 million in 2025.
  • Business Quant data shows EBIT for GH at -$120.8 million in Q4 2025, -$99.0 million in Q3 2025, and -$106.4 million in Q2 2025.